Jove
Visualize
Contact Us

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

2.4K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

363
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
363
Vaccinations01:51

Vaccinations

45.2K
Overview
45.2K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

302
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
302
Pneumonia IV: Management01:28

Pneumonia IV: Management

426
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
426
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

429
The pathophysiology of pneumonia involves the following steps:
429

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adverse childhood experiences and implementing trauma-informed primary care.

The Nurse practitioner·2018
Same author

Case Management and the Documentation of Avoidable Days.

Professional case management·2017
Same author

Patient-centered group diabetes care: a practice innovation.

The Nurse practitioner·2013
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.1K

Pneumococcal vaccination for adults: History and updates.

Jana L Esden1

  • 1Jana L. Esden is an associate professor at Frontier Nursing University in Versailles, Ky and a member of The Nurse Practitioner Editorial Advisory Board.

The Nurse Practitioner
|October 26, 2022
PubMed
Summary

Pneumococcal pneumonia remains a significant health concern despite vaccination efforts. Recent updates introduce two new conjugate vaccines for adults aged 19 and older to combat this disease.

More Related Videos

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.7K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.6K

Related Experiment Videos

Last Updated: Aug 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.1K
Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.7K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.6K

Area of Science:

  • Medicine
  • Infectious Diseases
  • Vaccinology

Background:

  • Pneumococcal infections, particularly pneumonia, contribute significantly to illness and death in the US.
  • Existing pneumococcal vaccination programs have lowered infection rates but have not eliminated the disease burden.

Purpose of the Study:

  • To inform healthcare providers and the public about updated pneumococcal vaccination recommendations.
  • To highlight the introduction of new pneumococcal conjugate vaccines for adult immunization.

Main Methods:

  • Review of recent clinical data and epidemiological trends in pneumococcal disease.
  • Analysis of updated guidelines from public health organizations regarding adult vaccination.

Main Results:

  • Pneumococcal pneumonia persists as a major cause of morbidity and mortality.
  • Two novel pneumococcal conjugate vaccines are now available for adults aged 19 years and older.

Conclusions:

  • Updated vaccination strategies are crucial for further reducing the impact of pneumococcal pneumonia.
  • The new vaccines represent an important advancement in protecting the adult population against pneumococcal disease.